Scientific topics
Keywords
ITMO
Jean-Marc BRONDELLO Ph.D life Science and cellular Biology
Course and current status
Jean-Marc Brondello studied Pharmacology and Cellular Biology at the University of Nice (France) and completed his PhD on the role of MKPs in cell proliferation at Jacques Pouyssegur’s lab in Nice (France).
He then moved to California at The Scripps Research Institute (La jolla, USA) to perform a 4-year postdoctoral training in Paul Russell’s Lab working on DNA damage checkpoint and cell cycle regulation
In 2002, he was nominated as Research Associate at INSERM and developed projects on DNA damage checkpoint regulation linked to cellular senescence and cancer. In 2005, he was the laureate of French-Canadian exchange program and was invited at the University of Montreal (Qc, Canada).
In 2008, he jointed as research scientist the INSERM Unit directed by Christian Jorgensen at Montpellier (France), where he sought to link between cellular senescence and osteoarticular disease development.
Since 2015, as member of the national INSERM consortium on aging studies: AGEMED, he is managing a research group entitled “innovative senotherapeutic strategies applied to osteoarticular diseases and Regenerative Medicine” at the Institute for Regenerative Medicine and Biotherapy, IRMB, U1183 Montpellier, France.
Current address:
Institute For Regenerative Medicine and Biotherapy (IRMB) INSERM U1183
Group Leader "innovative senotherapies in Regenerative Medicine" Team 2 Group 3
CHU St Eloi, 34295 Montpellier cedex 05, France
RESEARCH GRANTS, FELLOWSHIPS and AWARDS
2023-2025 Projet FUFaging SATTLR/Montpellier University (Co-applicant)
2023-2025 Projet Emergence SFR (Co-PI)
2023-2024 Clinical project MOuv GoPro (partner)
2023-2026 Collaborative support Grant from Montpellier Univ (PI)
2023-2026 Industrial Ph D Fellowship (PI)
2021-2022: BIOMARKER MUSE Montpellier Univ (PI)
2021-2022: Grant APHP OSCAR (PI)
2021-2024: Regional Grant on aging therapies: SenoCure (PI)
2020-2023: Industrial Ph D fellowship (PI)
2020-2023: CHU-UM RegenHab FHU Ph.D fellowship (PI)
2019-2022: Comparative senescence phenotypes associated to Covid-19 (co-applicant)
2016-2023 : National INSERM consortium on aging AGEMED (co-laureate)
2020-2021: Industrial grant "senoCure" (PI)
2019-2020 : Montpellier University initial grant : osteoarthritis therapies (PI)
2015-2017 : Industrial grant « Senestem » (co-laureate)
2015-2018 : ANR « Mitostem » (co-laureate)
2014-2015 : ITMO aging « Rejuvstem » (co-lauréate)
2013-2015 : Research grant "Fondation de l’Avenir" (PI)
2009-2012 : Regional Ph.D fellowship Université de Montpellier (co-laureate)
2008-2011 : Research grant FRM (co-laureate)
2005-2006 : french-canadian exchange program fellowship : IRSC-INSERM (PI)
2004-2007 : Grant Cancérople Grand Sud-Ouest (projet 3R) (PI)
2001-2003 : Research grant ARC (PI)
1999-2000: california Leukemia society post-doctoral fellowship (PI)
TEACHING ACTIVITIES
2024-now : Co-manager of ImmunoCell on autoimmunity Diploma, Montpellier Univ
2021-now : Co-manager of Master 2 Ageing studies program, Montpellier University
2013-now : Molecular and proteomic studies (Licence Pro, Montpellier University
2015-now : senotherapies for elderly: Regenerative medicine diploma Montpellier university
2018-now: senotherapies: Master 2 Therapies Medecine Faculty Montpellier University
2017-now: senotherapies and regenerative medicine: Master 2 Montpellier University
2011-now : Senescence and checkpoint Master 2 Pharmacy faculty, Montpellier
2011-now : Senescence and epigenetic Master 2 Cell biology, Montpellier University
2015-2018 : Cellular biology practice in Licence, Montpellier University
2007-2012 : Project management in Biology Master Biotin , Montpellier University
INVITED or ORGANIZED CONFERENCES
2023: Journée de la société Oscar des tissus minéralisés, Paris (Invited)
2021: Journée Bichat-Beaujon Centre de recherche sur l"inflammation (invited)
2021: Journées Biomarkers days Université de Montpellier (invited)
2021: Seconde rencontre occitanie sur le vieillissement (organizer)
2020: 2nd longevity therapeutics symposium, San Francisco, (invited)
2019: Seminaire externe INRAE Unité Nutrition humaine Clermont-ferrand (invited)
2018: Rencontre Agemed Paris et Marseille (invited)
2018: Seminaire Département de Rhumatologie GIGA CHU de Liége, Belgique (invited)
2016: Premiere rencontre d'occitanie sur le vieillissement (scientific commitee),
2013: Journée de Rhumatologie MAMATO (invited)
2011: Rencontre Franco-Americaine FABS autour du viellissement (scientific commitee)
2008: 38e Congrès annuel de la société SFBBM, La grande Motte (Organizer)
2007: Institut de Neurosciences de Montpellier, (invited)
2005: Departement de Biochimie, Université de Montreal, (invited)
2004: Université de Paul Sabatier, Toulouse (invited)
2001: Centre de Biochimie Valrose, Université de Nice (invited)
INSTITUTIONAL RESPONSIBILITIES
- Responsibilities within the national and international scientific community
2023 HCERES evaluation commitee member as expert on joint studies
2021-now Elected member of INSERM CSS3 scientific evaluation commitee
2020-now Co-coordinator for innovative Senotherapy collaborative program, AGEMED
2021 Expertise for Region "Ile de France"
2020-2021 Editor at Cells
2015-now Grant per Reviewer for regional, national and international institutions
2004-now journal per reviewer for several journals
- Responsibilities within the Montpellier scientific community
2023-now Elected Representative for Regenerative Medecine axis at Montpellier Unv
2023-now Suppléant for F4SCT INSERM at DR Occitanie-Sud
2011-now Co-founder and animator of the Montpellier Aging Network
2014-now Educational committee member at IUT, Montpellier University
2013-now PhD and pharma D Thesis Jury Member (6 thesis defense)
2016-now Ph. D Student committee member (5 thesis), Montpellier University
2017-now Jury at University professional committee, Montpellier
2010-now Master 2 student jury, Montpellier University
2014-now Jury Member of the PhD Program Selection, Montpellier University, France
2016 scientific committee member on the first regional Aging symposium
2011 Scienfic committee member for the french-american FABS on aging
2008 Executive organizer committee for 38th SFBBM annual meeting
- Responsibilities within the INSERM Unit
2023- Green Lab commitee, IRMB, France
2015-2021 Equipment Committee leader, IRMB, France
2008-2015 Organizer of the scientific lecture committee, INM, France
2008-2015 Gaz and CO2 network manager
- Society Membership:
2012 Montpellier Aging Network (organizer)
2017 French society for Rhumatology
2017 French society for Stem cell research
2016 International cellular Senescence Association
Scientific summary
Osteoarthritis (OA) is the most common chronic degenerative disease having pejorative consequences on quality of life in elderly. OA has a huge impact on the public health costs. OA pathology is characterized by progressive cartilage alteration, osteophyte formation, sub-chondral bone sclerosis, and synovial inflammation. To date, no validated curative medical treatments are available for OA patients. New "symptomatic slow-acting drugs" such as glucosamine are used but they still lack evidence for efficiency on long-term structural articular remodeling. Therefore, OA still shows a huge unmet need while symptomatic painkiller treatments remain alternatives before prosthetic surgical joint replacement. To develop innovative treatments, we should decipher how OA-driven events could affect joint homeostasis. Remarkably recent works published by us and others have given new insights on the cellular mechanisms namely cellular senescence that could explain phenotypes accounting for OA development.
Accordingly, we found with others senescent cells expressing p16INK4a,p15INK4b and p21cdkn1a in cartilage, synovial and fat pad tissues from OA mice and OA patients. However, during the course of the disease, it still remains to decipher which, when and how articular joint cell-types are becoming senescent in order to propose innovative specific senotherapies for cartilage regeneration. Using in vivo transgenic murine models for senescence detection and depletion altogether with in vitro 2D and 3D senescent conditions on osteoarticular cells, our group aims at:
- identifying senescent articular joint cells that drive tissue degeneration
- developing strategies to eliminate and detect such cells in vitro and in vivo
- restoring joint functions in elderly to delay prosthetic surgery
